The FDA approved the drug aducanumab despite having no solid evidence that it does what it claims to do. Now Medicade is considering whether to cover the drug at an exorbitant price. If it does, every person with Medicare drug coverage would face considerable additional cost.

If Medicare could negotiate a price to buy this drug in bulk, it might get a reasonable price. It can't do so because of a law passed by plutocratistic officials.

However, giving millions of people a drug on the grounds that it might prevent a disease for some of them seems like getting ahead of the game.